Results 1 to 8 of 8

Thread: A Review of 18 Companies That Have the Ability to Make a Difference in the Stem Cell

  1. #1

    A Review of 18 Companies That Have the Ability to Make a Difference in the Stem Cell

    http://www.marketwatch.com/news/news...tegories=&
    A Review of 18 Companies That Have the Ability to Make a Difference in the Stem Cell Industry
    1/23/2006 1:15:01 PM

    DUBLIN, Ireland, Jan 23, 2006 (BUSINESS WIRE) -- Research and Markets (http://www.researchandmarkets.com/reports/c31288 ) has announced the addition of Stem Cell Companies: 18 Lead the Way to their offering.

    Many companies have jumped on the stem cell band wagon, but only a few are truly performing breakthrough research in the area. This report identifies the 18 companies world-wide that have the potential to make a difference and explores their technologies and likelihood of success. Each company's research and clinical trial pipeline as well as the successes and failures are examined. An additional 14 companies contributing to stem cell research as collaborators, investors or partners are also identified.

    A few of the "real" stem cell 18 companies include:

    -- Ceregene, Inc. (US)

    -- Geron Corporation (US)

    -- Novocell, Inc. (US)

    -- NsGene A/S (Denmark)

    -- ReNeuron Group plc (UK)

    -- StemCells Inc. (US)

    -- ViaCell Inc. (US)
    <companies mentioned>
    Companies Mentioned
    Aastrom Biosciences Inc.
    Advanced Cell Technology Inc.
    Amgen
    Amersham
    AstraZeneca
    Biogen Idec
    BresaGen Ltd.
    Cell Genesys
    Cellartis AB
    Cellular Dynamics International
    Ceregene, Inc.
    Covance
    Cytori Therapeutics, Inc.
    Genentech
    Genesys Inc.
    Genzyme
    Geron Corporation
    Incyte
    Johnson & Johnson
    Layton Bioscience Inc.
    Merck
    Novartis AG
    Novocell, Inc.
    NsGene A/S
    Quintiles
    ReNeuron Group plc
    Schering AG
    Stem Cell Therapeutics Corp.
    StemCells Inc.
    Titan Pharmaceuticals Inc.
    Transition Therapeutics Inc.
    TriStem Corporation
    ViaCell Inc.
    [/quote]

  2. #2
    Senior Member
    Join Date
    Jun 2005
    Location
    Norway
    Posts
    17,427
    Thanks for the post. I see this is only private companies – I’m wondering how many government owned universities/hospitals are working on stem cells which can make a difference. Does anybody know actually how many stem cell centres there are around the world? Approx?

  3. #3
    Quote Originally Posted by Leif
    Thanks for the post. I see this is only private companies – I’m wondering how many government owned universities/hospitals are working on stem cells which can make a difference. Does anybody know actually how many stem cell centres there are around the world? Approx?
    Check here for some: http://www.cureparalysisnow.org/foru...dfe1a3afc35cbd

  4. #4
    Senior Member
    Join Date
    Jun 2005
    Location
    Norway
    Posts
    17,427
    Sorry - your link would not open Pro-SCNT.

  5. #5
    Senior Member
    Join Date
    May 2005
    Location
    Pakistan
    Posts
    1,169
    Dear Leif Hope you will be fine. Never forget you are amongst my favourite CC Members. God bless you. Always smile and live happy.


    Dear Young TriStem is already treating patients here in pakistan and tell some good results too. When i did contact to them they are hopeful for my good recovery as you know i am incomplete with L1 compression. They say that i can regain bladder bowel and sexual function. Though not much confident but still reasonable for recovery.

    I need to know from you is that is TriStem reliable and i should go for treatment? Hope you will advise best. God bless you and keep you happy and healthy longer.

    Jawaid

  6. #6
    Banned Faye's Avatar
    Join Date
    May 2003
    Location
    Jacksonville, FL
    Posts
    6,839

    Stem Cell Therapies and Regenerative Medicine: Current Applications

    B-153R Stem Cell Therapies and Regenerative Medicine: Current Applications and Future Possibilities

    Steven Edwards, Ph.D.

    Published December 2005
    $3,950.00 for full report (add 15% for PDF version)
    Page and Chapter Pricing Available - Go to "Purchase On-line"
    2002 Version Available
    REPORT HIGHLIGHTS
    • The worldwide market for stem cell, cytokine and growth factor therapies is estimated at $12.7 billion in 2005 and, rising at an average annual growth rate (AAGR) of 10.3%, is expected to reach $20.7 billion in 2010.
    • Nearly 98% of the market is consumed by blood and immune system treatments, a figure that will shrink slightly to 95% in 2010.
    • Revenues worldwide for stem cell, cytokine and growth factor therapies for all other bodily systems are expected to rise at an AAGR of 26.4% to just over $1 billion in 2010.
    • The first off-the-shelf cell therapy approved by the FDA was for wound treatment. Recently, a bone morphogenic protein (BMP) has been approved for the acceleration of spinal fusions.
    Global Forecast of Revenues for Stem Cell and Cytokine Therapies in Regenerative Medicine, 2003-2010
    ($ Billions)

    Source: BCC, Inc.

    INTRODUCTION
    In March 2002, BCC published its first study focused on stem cells and progenitor cell therapy. Since that time, stem cell and regenerative companies have had a difficult time because of a shortage of funding. However, new companies have sprung up, as new research prompts new avenues of exploration.

    The political climate for embryonic stem cells has changed. The Bush Administration maintains a ban in the U.S. on federal funding for research using newly established lines. However, California and Illinois have begun funding this research and others seem likely to follow. The House of Representatives has passed a bill reversing Bush's ban, and the Senate is likely to pass it. Meanwhile, other countries are making embryonic stem cell research a priority. For most of 2005, for instance, it seemed as if South Korean scientists had surpassed the rest of the world in the ability to generate patient-specific embryonic stem cells through nuclear transfer. It now appears that these results were fabricated; respectable peer-reviewed journals were taken in by the hoax because the achievements described were quite feasible, given similar results acheived in animal studies.

    Given these many changes taking place in regenerative medicine, it seems a good time to renew our study of this field. This comprehensive and cohesive technical market research report from BCC is set within the existing regulatory framework and takes into account not only technical accomplishments but also political and financial realities. The study, therefore, establishes the necessary context from which to make rational decisions regarding business decisions in this expanding field.
    SCOPE OF STUDY
    The report contains:
    • An overview that introduces the various kinds of stem cells, gives definitions, and discusses political, regulatory aspects, and the major developments of 2005 including the retraction of previously published South Korean stem cell research results
    • Analysis of applications including current and potential cytokine and cell therapies with forecasts through 2010
    • A discussion of current products as well as many that are still in clinical trials
    • An industry structure analysis including companies in the field and their focus
    • Profiles of individual companies, and includes the names of key officers.

    METHODOLOGY AND INFORMATION SOURCES
    The information reported herein has been gathered from a variety of industry and other sources. The 10K forms and other SEC filings from public companies have been examined along with annual reports, catalogues, and press releases. The World Wide Web is a rich source of information, as almost every commercial concern now has its own Web page. Where appropriate, medical literature and scientific literature have served as a research source.

    We have also gathered statistical information from the U.S. government, the World Health Organization, and private foundations. Armed with the industry and statistical information garnered all of these sources, market participants were interviewed to fill in the gaps.
    ANALYST'S CREDENTIALS
    The author of this report, Steven Edwards, Ph.D., has a broad background in the biological and health sciences, and is well acquainted with advanced technology. He received his doctorate in biology from the University of California, San Diego. His thesis work centered on the expression of murine leukemia virus genes, and he was awarded a National Institutes of Health (NIH) postdoctoral fellowship to study neuroendocrinology at the Salk Institute. Subsequently, Dr. Edwards was a Research Associate at La Jolla Cancer Research Foundation (now Burnham Institute), where he studied developmental regulation of gene transcription in teratocarcinoma cells (cells similar to embryonic stem cells). Later, he was appointed assistant professor in the biochemistry department of Meharry Medical College (Nashville, TN). There he directed a research laboratory studying transcriptional regulation, supported by grants from the American Heart Association and the NIH.

    Dr. Edwards is now a medical industry analyst, and science writer and editor. He has been the editor of several BCC newsletters: Applied Genetics News, Drug Discovery/Technology News, Cell Therapy News, and Nano/Bio Convergence News, and is now editor of Biomolecular Diagnostic News. His journalistic work has also appeared in Massachusetts Institute of Technology's (MIT's) Technology Review, Diabetes Forecast, Genetic Engineering News, and other publications. He is a frequent contributor to RedzoneProfits (Website: www.redzoneprofits.com), an Internet-based investment newsletter that focuses on emerging technology companies.

    Dr. Edwards was the project analyst responsible for the BCC reports B-119 Cell Therapy and Tissue Engineering, Emerging Products (1998); B-127 Microelectronic Medical Implants, Products, Technology and Opportunity (1999); B-143 Bones and Joints: Drugs, Devices, and Regenerative Technologies (2000); Progenitor and Stem Cell Therapy: Current Uses and Future Possibilities (2002); B-162 Biomedical Applications of Nanoscale Devices (2003); and B-192 Beyond Chemotherapy: Battling Cancer with Biotechnology (2004). He is also the author of The Nanotech Pioneers: Where are they taking us?, a book due to be published by Wiley-VCH Verlag GmbH & Co. in January 2006.

    Dr. Edwards has served as vice president for technologies for Phaelixe, Inc., a consulting firm in Denver, CO. He has also consulted for a venture capital company, and has served as program chairman for several nanotech and nanobiotech conferences hosted by BCC. .
    OTHER RELEVANT BCC REPORTS AND PUBLICATIONS

    TABLE OF CONTENTS

    INTRODUCTION
    XVIREASON FOR DOING THE STUDY
    XVISTUDY GOAL AND OBJECTIVES
    XVICONTRIBUTIONS OF THE STUDY AND FOR WHOM
    XVIISCOPE AND FORMAT
    XVIIMETHODOLOGY AND INFORMATION SOURCES
    XVIIIANALYST'S CREDENTIALS
    XVIIIOTHER RELEVANT BCC REPORTS AND PUBLICATIONS
    XIXBCC ONLINE SERVICES
    XXDISCLAIMER
    XXSUMMARY
    XXISummary Table:
    GLOBAL FORECAST OF REVENUES FOR STEM CELL AND CYTOKINE THERAPIES IN REGENERATIVE MEDICINE, THROUGH 2010 ($ BILLIONS)
    XXIISummary Figure:
    GLOBAL FORECAST OF REVENUES FOR STEM CELL AND CYTOKINE THERAPIES IN REGENERATIVE MEDICINE, 2003-2010 ($ BILLIONS)
    XXIIIOVERVIEW
    1Table 1 PERCENT OF PERSONS USING PRESCRIPTION DRUGS IN THE PAST MONTH IN THE U.S., 1999-2000
    1GROWTH FACTORS AND CYTOKINES
    1Table 2 SELECTED CYTOKINES OR GROWTH FACTORS RELEVANT TO REGENERATIVE MEDICINE
    2Table 2 (CONTINUED)
    3STEM AND PROGENITOR CELLS
    3WORLDWIDE MARKETS FOR REGENERATIVE MEDICINE
    4Table 3 LEADING CAUSES OF DEATH IN THE U.S., 2001
    5Table 4 PREVALENCE OF MEDICAL CONDITIONS IN THE U.S. WITH POTENTIAL CELL THERAPIES
    6Table 5 AGING OF THE U.S. POPULATION
    6CELL THERAPIES AS A SUBSTITUTE FOR TRANSPLANTS
    7THE U.S. MARKET VERSUS THE REST OF THE WORLD
    7The U.S. Market versus the (Continued)
    8Table 6 POPULATION OF COUNTRIES OF THE EUROPEAN UNION, 2003
    9DISTRIBUTION OF REVENUES AND EFFORT
    10TYPES OF STEM OR PROGENITOR CELLS
    11Table 7 DESCENDANTS OF THE HUMAN MESENCHYMAL STEM CELL
    12Autologous Cells
    13Allogeneic Cells
    14UMBILICAL CORD BLOOD
    14Table 8 A PARTIAL LIST OF DISEASES TREATED USING CORD BLOOD STEM CELLS
    15EMBRYONIC STEM CELLS
    16Embryonic Stem Cells (Continued)
    17Table 9 DERIVATION OF BODY TISSUE TYPES FROM GERM LAYERS
    18Table 10 CELL TYPES DERIVED FROM EMBRYONIC STEM CELLS IN VITRO
    18Table 10 (CONTINUED)
    19Identification of Stem Cells
    19Table 11 MARKERS OF PLURIPOTENT CELLS IN MOUSE, MAN, AND MONKEY
    20Therapeutic Cloning
    20Therapeutic Cloning (Continued)
    21Utility of ES Cells
    22Ethical Considerations
    23Position of the Catholic Church
    24Position of the National Academy of Sciences
    25Politics and Funding for Embryonic Stem Cell Research
    26Politics and Funding for Embryonic Continued)
    27NIH Guidelines
    28NIH Guidelines (Continued)
    29Table 12 EMBRYONIC STEM CELL LINES THAT MEET NIH FUNDING REQUIREMENTS, WHICH ARE AVAILABLE FOR SHIPPING
    30Patents
    30GERM CELLS
    31WHAT MAKES A STEM CELL A STEM CELL?
    31CELL-BASED GENE THERAPY
    32U.S. REGULATION
    33DEVICES
    33Table 13 FOOD AND DRUG ADMINISTRATION BODIES INVOLVED IN IMPLANT REGULATION
    34BIOLOGICALS
    35Biologicals (Continued)
    36ORPHAN PRODUCT STATUS
    37INTERNATIONAL ISSUES
    37OFFSHORE CELL-THERAPY TREATMENTS
    38OFFSHORE CELL-THERAPY TREATMENTS (CONTINUED)
    39APPLICATIONS FOR PROGENITOR CELL THERAPIES
    40APPLICATIONS OF REGENERATIVE MEDICINE FOR BLOOD AND THE IMMUNE SYSTEM
    40Figure 1 HEMATOPOIESIS
    41APPLICATIONS OF REGENERATIVE CONTINUED)
    42Table 14 A PARTIAL LIST OF DISEASES TREATED WITH HEMATOPOIETIC STEM CELLS
    43Table 14 (CONTINUED)
    44HARVESTING HEMATOPOIETIC STEM CELLS
    44Bone Marrow
    44Peripheral Blood Progenitor Cell Collection
    45Umbilical Cord Blood
    46Drug-Resistant Hematopoietic Stem Cells
    46PRODUCTS AND SERVICES IN SUPPORT OF HEMATOPOIETIC STEM CELL TRANSFERS
    47Table 15 COMMERCIAL OPPORTUNITIES FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
    48CYTOKINES FOR STEM CELL THERAPY
    49Table 16 APPROVED BIOPHARMACEUTICALS FOR THE REGENERATION OF BLOOD AND IMMUNE CELLS AFTER CHEMOTHERAPY
    50G-CSF and GM-CSF
    50AMD3100
    51Erythropoietins
    51MARKET OPPORTUNITIES FOR REGENERATIVE CYTOKINES
    52Table 17 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, THROUGH 2010 ($ MILLIONS)
    53Figure 2 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, 2003-2010 ($ MILLIONS)
    53HARVESTING AND STORAGE OF UMBILICAL CORD BLOOD
    54Table 18 COMMERCIAL UMBILICAL CORD BLOOD STORAGE COMPANIES
    55Market Opportunities for Umbilical Cord Blood Storage
    56Table 19 FEES CHARGED BY MAJOR UMBILICAL CORD BLOOD BANKS, 2005 ($)
    57Table 20 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, THROUGH 2010 ($ MILLIONS)
    58Figure 3 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, 2003-2010 ($ MILLIONS)
    58EXPANSION OF STEM CELLS
    58Expansion of Stem Cells (Continued)
    59Market Opportunities for Stem Cell Expansion.
    60Table 21 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, THROUGH 2010 ($ MILLIONS)
    60Figure 4 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, 2003-2010 ($ MILLIONS)
    61GRAFT-VERSUS-HOST DISEASE
    61IMMUNE DEFICIENCIES
    62Acquired Immunodeficiency Syndrome
    63Table 22 AQUIRED IMMONDEFICIENCY CASES REPORTED BY YEAR IN THE U.S., 1985-2003
    64Natural Resistance
    64Current Therapies for AIDS
    65Progenitor Cell Therapies for AIDS
    65Market Opportunities for AIDS Therapies
    66Table 23 SIZE OF THE AIDS/HIV EPIDEMIC
    66SUMMARY: BLOOD AND IMMUNE DISEASES
    67Table 24 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS)
    67Table 5 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS)
    68SKIN
    68SKIN CELL PROGENITORS
    69BURNS
    69ULCERS
    70ULCERS (CONTINUED)
    71MARKET OPPORTUNITIES FOR SKIN CELL THERAPIES
    72MARKET OPPORTUNITIES FOR SKIN CELL THERAPIES (CONTINUED)
    73Table 25 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, THROUGH 2010 ($ MILLIONS)
    74Figure 6 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, 2003-2010 ($ MILLIONS)
    74BONE
    74BONE FRACTURES
    75Bone Metabolism
    76Current Therapies
    77Cell Therapies for Bone Fractures
    77Growth Factors and Morphogenic Proteins
    78Table 26 GROWTH FACTOR PRODUCTS FOR BONE HEALING
    79Table 27 GROWTH FACTORS DEVELOPED BUT NOT YET APPROVED FOR BONE INDICATIONS
    80Market Opportunities for Regenerative Therapies for Fractures and Spinal Fusions
    80Table 28 SPINAL FUSION DATA, U.S. 1998-2002 ($)
    81Table 29 NUMBER OF LOWER LEG FRACTURE, 1998-2002
    81Table 30 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS)
    82Figure 7 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS)
    82CARTILAGE
    83Table 31 PRODUCTS FOR REGENERATIVE CARTILAGE REPAIR
    83MENISCUS REPAIR
    83INJURIES OF THE KNEE
    84INTERVERTEBRAL DISC REGENERATION
    85MARKETS FOR CARTILAGE REPAIR
    85Table 32 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, THROUGH 2010 ($ MILLIONS)
    86Figure 8 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, 2003-2010 ($ MILLIONS)
    87CARDIOVASCULAR SYSTEM
    87CONGESTIVE HEART FAILURE
    88Current Therapies
    88CORONARY HEART DISEASE
    89Current Therapies
    89CELL THERAPIES FOR CHF OR CORONARY DISEASE
    89Cell Therapies for CHF or Coronary Disease (Continued)
    90Cell Therapies for CHF or Coronary Disease (Continued)
    91CARDIAC ARRYTHMIA
    92Current Therapy
    92Cell Therapies
    93MARKET OPPORTUNITIES FOR CARDIOVASCULAR CELL THERAPIES
    93Table 33 PREVALENCE OF HEART DISEASE IN U.S. ADULTS (18 YEARS AND OVER), 2002 (THOUSAND)
    94TEETH
    95HAIR
    95BRAIN AND NERVOUS SYSTEM
    96NEURAL STEM CELLS
    97LYSOSOMAL STORAGE DISEASES
    97DISORDERS OF THE MYELIN SHEATH
    98SPINAL CORD INJURY
    99Spinal Cord Injury (Continued)
    100STROKE
    101Table 34 DEATH RATES PER 100,000 FROM CEREBROVASCULAR DISEASE (STROKE) IN THE U.S., 1960 AND 2002
    102PARKINSON'S DISEASE
    103Cell Therapies
    103Cell Therapies (Continued)
    104The Market Opportunities for Regenerative Treatments to Treat Neural Disease
    105EYES
    105EYES (CONTINUED)
    106Market Opportunities
    107LIVER
    108HUMAN CELL THERAPIES
    109Human Cell Therapies (Continued)
    110Markets for Regenerative Therapies for the Liver
    111KIDNEY
    111Potential Cell Therapies for Kidney Disease
    112Market Opportunities for Regenerative Kidney Therapies
    113DIABETES
    113Table 35 GLOBAL PREVALENCE OF DIABETES IN EUROPE, AGES 20 TO 79 2003 AND 2025 (THOUSANDS)
    114COMPLICATIONS OF DIABETES
    115Current Treatments
    115Edmonton Protocol
    116STEM CELL THERAPIES
    116Market Opportunities for Regenerative Diabetes Therapies
    117REPRODUCTIVE MEDICINE
    118MARKET OPPORTUNITIES FOR OOCYTE CRYOPRESERVATION
    119Table 36 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, THROUGH 2010 ($ MILLION)
    120Figure 9 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, 2003-2010 ($ MILLION)
    120PRODUCTS USED IN CELL THERAPY AND REGENERATIVE MEDICINE
    121PRODUCTS USED FOR AMPLIFYING, CULTURING, OR TRANSFERRING STEM CELLS
    121AASTROMREPLICELL SYSTEM
    121MYOCATH PERCUTANEOUS DELIVERY SYSTEM
    122PLURIX BIOREACTOR SYSTEM
    123CYTOMATRIX
    123CYTOKINES AND GROWTH FACTORS
    124Table 37 CYTOKINES AND GROWTH FACTORS IN REGENERATIVE MEDICINE
    124AMD3100
    125ARANESP
    125BMP-7
    126CHRYSALIN
    126CTCE-0214
    126CYT 99 007
    127EPOGEN/PROCRIT
    127INFUSE/INDUCTOS
    128NEULASTA
    128NEUMEGA
    129NEUPOGEN
    129OP-1
    130REGRANEX GEL
    131THYMOSIN BETA FOUR
    131TUMOR GROWTH FACTOR ALPHA
    132LIVING CELL THERAPIES
    132HEMATOPOIETIC AND IMMUNE CELL THERAPIES
    133Table 38 LIVING BLOOD AND IMMUNE CELL THERAPEUTIC PRODUCTS IN DEVELOPMENT
    133Highly Purified Hematopoietic Stem Cells
    134HGTV-43
    134MP Cells
    135Procord
    136SKIN
    136Table 39 LIVING SKIN EQUIVALENTS USED THERAPEUTICALLY
    136Apligraf
    137Dermagraft
    137EpiCel
    138Hyalograft 3D
    138Laserskin Autograft
    138OrCel
    139CARTILAGE
    139Table 40 LIVING-CELL PRODUCTS USED THERAPEUTICALLY TO REPAIR CARTILAGE
    139Carticel
    139Cartilink
    140Chondrogen
    141Co.Don Chondrotransplant
    141Co.Don Chondrotransplant DISC
    141Hyalograft C
    142ICX-PRO
    142ICX-SKN
    142NEURAL STEM CELLS
    143HuCNS-SC
    143MUSCLE
    143Table 41 MUSCLE CELLS USED AS THERAPEUTIC PRODUCTS
    143Biopace
    143MyoCell
    144Myocell VT
    144Provacel
    145OTHER MESENCHYMAL CELLS
    145Prochymal
    145Tissue Repair Cells - Aastrom Bioscience
    146PANCREAS
    146IxSC-1
    146KIDNEY
    147Renal Assist Device
    147STEM CELL STORAGE
    147BIOARCHIVE STEM CELL SYSTEM
    147CCEL CELLULAR STORAGE FREEZER
    148STRUCTURE OF THE INDUSTRY
    149CYTOKINE AND GROWTH FACTOR COMPANIES
    149Table 42 COMPANIES SUPPLYING APPROVED CYTOKINE OR GROWTH FACTOR THERAPIES
    149MARKET SHARES OF CYTOKINE AND GROWTH FACTOR COMPANIES
    150Table 43 RANKINGS AND MARKET SHARES OF COMPANIES FOR CYTOKINES AND GROWTH FACTORS IN 2004 (REVENUES)
    150PRODUCTS UNDER DEVELOPMENT
    150Table 44 COMPANIES DEVELOPING GROWTH FACTOR OR CYTOKINE PRODUCTS
    151UMBILICAL CORD STEM CELL COMPANIES
    151Table 45 2004 WORLDWIDE MARKET RANKINGS FOR UMBILICAL CORD STEM CELL STORAGE COMPANIES
    151CELL THERAPY COMPANIES
    152Table 46 FOCUS OF STEM AND PROGENITOR CELL THERAPY COMPANIES
    152Table 46 (CONTINUED)
    153Table 46 (CONTINUED)
    154PATENTS
    154PATENTS (CONTINUED)
    155Table 47 U.S. PATENT APPLICATIONS FROM JANUARY 1, 2001 THROUGH SEPTEMBER 8, 2005, WITH SELECTED STEM CELL SEARCH TERMS
    156Table 48 SELECTED U.S. STEM CELL PATENTS ISSUED BETWEEN JANUARY 2002 AND SEPTEMBER 2005
    157Table 48 (CONTINUED)
    158Table 48 (CONTINUED)
    159Table 48 (CONTINUED)
    160ATTRITION
    160Table 49 DISAPPEARING NAMES IN REGENERATIVE MEDICINE
    161COMPANY PROFILES
    162AASTROM BIOSCIENCES
    162ADERANS RESEARCH INSTITUTE
    162ADVANCED CELL TECHNOLOGY
    163ADVANCED CELL THERAPEUTICS
    164AMGEN
    164ANORMED
    165ATHERSYS
    165BAXTER INTL.
    166BEFUTUR BIOTECHNOLOGIES
    166BIOHEART
    167BIOMATRIX SCIENTIFIC GROUP
    168BIOTISSUE, INC.
    168BIOTISSUE TECHNOLOGIES AG
    168BRAINSTORM CELL THERAPEUTICS
    169CELLARTIS
    170CELL BASED DELIVERY
    170CELLERANT THERAPEUTICS
    171CELLRESEARCH CORP.
    171CELLULAR DYNAMICS
    172CHEMOKINE THERAPEUTICS
    172CO.DON AG
    173CORCELL
    173CORD BLOOD AMERICA
    173CORD BLOOD REGISTRY
    174CYGENICS
    174CORDLIFE PTE, LTD./ CELL SCIENCES PTE, LTD.
    174CYTOMATRIX
    175CRYO-CELL INTL.
    175CYTHERA
    176CYTORI THERAPEUTICS
    176DENTIGENIX, INC.
    177ENCELLE
    177ENZO BIOCHEM
    178EXTENDFERTILITY
    179FIDIA FARMACEUTICI SPA
    179FREZER, INC.
    179GENZYME BIOSURGERY
    180GENVEC
    181GERON
    181HISTOSTEM
    182INTERCYTEX
    182INTERFACE BIOTECH A/S
    183ISLET TECHNOLOGY
    183ISTO TECHNOLOGIES
    184IXION BIOTECHNOLOGY
    185KALEIDOS PHARMACEUTICAL
    185JOHNSON & JOHNSON
    186LIFEBANK CRYOGENICS
    186MEDRA
    187MESOBLAST, LTD.
    187MILTENYI BIOTEC GMBH
    188MORPHOGENESIS
    188NEOSTEM
    189NEPHROS THERAPEUTICS
    189NEURALSTEM BIOPHARMACEUTICALS
    190NEURONYX
    190NOVARTIS INTERNATIONAL AG
    191NS GENE A/S
    191ODONTIS
    192ORGANOGENESIS
    192ORTEC INTL.
    193ORTHOLOGIC
    193OSIRIS THERAPEUTICS
    194PHARMA FRONTIERS
    194PHARMASTEM THERAPEUTICS
    195PLURISTEM LIFE SYSTEMS
    195PRIMEGEN BIOTECH, LLC
    196PROGENITOR CELL THERAPY
    196PRONEURON BIOTECHNOLOGIES
    197REGENERX BIOPHARMACEUTICALS
    197RENEURON
    198SANERON CCEL THERAPEUTICS, INC.
    198STEMCELLS, INC.
    199STEMCELL PHARMA, INC.
    199STEM CELL SCIENCES
    200STEM CELL THERAPEUTICS CORP.
    200STEM CELL THERAPY INTL.
    201THERMOGENESIS
    202TISSERA
    202U.S. BIODEFENSE, INC.
    202VESTA THERAPEUTICS
    203VIACELL
    203WICELL RESEARCH INSTITUTE
    204APPENDIX
    205GLOSSARY OF TERMS AND ABBREVIATIONS
    205GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
    206GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
    207GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
    208GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
    209GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
    210GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
    211GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
    212GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
    213 LIST OF TABLES

    Summary Table:
    GLOBAL FORECAST OF REVENUES FOR STEM CELL AND CYTOKINE THERAPIES IN REGENERATIVE MEDICINE, THROUGH 2010 ($ BILLIONS)
    XXIITable 1 PERCENT OF PERSONS USING PRESCRIPTION DRUGS IN THE PAST MONTH IN THE U.S., 1999-2000
    1Table 2 SELECTED CYTOKINES OR GROWTH FACTORS RELEVANT TO REGENERATIVE MEDICINE
    2Table 3 LEADING CAUSES OF DEATH IN THE U.S., 2001
    5Table 4 PREVALENCE OF MEDICAL CONDITIONS IN THE U.S. WITH POTENTIAL CELL THERAPIES
    6Table 5 AGING OF THE U.S. POPULATION
    6Table 6 POPULATION OF COUNTRIES OF THE EUROPEAN UNION, 2003
    9Table 7 DESCENDANTS OF THE HUMAN MESENCHYMAL STEM CELL
    12Table 8 A PARTIAL LIST OF DISEASES TREATED USING
    15CORD BLOOD STEM CELLS
    15Table 9 DERIVATION OF BODY TISSUE TYPES FROM GERM LAYERS
    18Table 10 CELL TYPES DERIVED FROM EMBRYONIC STEM CELLS IN VITRO
    18Table 11 MARKERS OF PLURIPOTENT CELLS IN MOUSE, MAN, AND MONKEY
    20Table 12 EMBRYONIC STEM CELL LINES THAT MEET NIH FUNDING REQUIREMENTS, WHICH ARE AVAILABLE FOR SHIPPING
    30Table 13 FOOD AND DRUG ADMINISTRATION BODIES INVOLVED IN IMPLANT REGULATION
    34Table 14 A PARTIAL LIST OF DISEASES TREATED WITH HEMATOPOIETIC STEM CELLS
    43Table 15 COMMERCIAL OPPORTUNITIES FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
    48Table 16 APPROVED BIOPHARMACEUTICALS FOR THE REGENERATION OF BLOOD AND IMMUNE CELLS AFTER CHEMOTHERAPY
    50Table 17 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, THROUGH 2010 ($ MILLIONS)
    53Table 18 COMMERCIAL UMBILICAL CORD BLOOD STORAGE COMPANIES
    55Table 19 FEES CHARGED BY MAJOR UMBILICAL CORD BLOOD BANKS, 2005 ($)
    57Table 20 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, THROUGH 2010 ($ MILLIONS)
    58Table 21 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, THROUGH 2010 ($ MILLIONS)
    60Table 22 AQUIRED IMMONDEFICIENCY CASES REPORTED BY YEAR IN THE U.S., 1985-2003
    64Table 23 SIZE OF THE AIDS/HIV EPIDEMIC
    66Table 24 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS)
    67Table 25 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, THROUGH 2010 ($ MILLIONS)
    74Table 26 GROWTH FACTOR PRODUCTS FOR BONE HEALING
    79Table 27 GROWTH FACTORS DEVELOPED BUT NOT YET APPROVED FOR BONE INDICATIONS
    80Table 28 SPINAL FUSION DATA, U.S. 1998-2002 ($)
    81Table 29 NUMBER OF LOWER LEG FRACTURE, 1998-2002
    81Table 30 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS)
    82Table 31 PRODUCTS FOR REGENERATIVE CARTILAGE REPAIR
    83Table 32 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, THROUGH 2010 ($ MILLIONS)
    86Table 33 PREVALENCE OF HEART DISEASE IN U.S. ADULTS (18 YEARS AND OVER), 2002 (THOUSAND)
    94Table 34 DEATH RATES PER 100,000 FROM CEREBROVASCULAR DISEASE (STROKE) IN THE U.S., 1960 AND 2002
    102Table 35 GLOBAL PREVALENCE OF DIABETES IN EUROPE, AGES 20 TO 79, 2003 AND 2005 (THOUSANDS)
    114Table 36 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, THROUGH 2010 ($ MILLION)
    120Table 37 CYTOKINES AND GROWTH FACTORS IN REGENERATIVE MEDICINE
    124Table 38 LIVING BLOOD AND IMMUNE CELL THERAPEUTIC PRODUCTS IN DEVELOPMENT
    133Table 39 LIVING SKIN EQUIVALENTS USED THERAPEUTICALLY
    136Table 40 LIVING-CELL PRODUCTS USED THERAPEUTICALLY TO REPAIR CARTILAGE
    139Table 41 MUSCLE CELLS USED AS THERAPEUTIC PRODUCTS
    143Table 42 COMPANIES SUPPLYING APPROVED CYTOKINE OR GROWTH FACTOR THERAPIES
    149Table 43 RANKINGS AND MARKET SHARES OF COMPANIES FOR CYTOKINES AND GROWTH FACTORS IN 2004 (REVENUES)
    150Table 44 COMPANIES DEVELOPING GROWTH FACTOR OR CYTOKINE PRODUCTS
    151Table 45 2004 WORLDWIDE MARKET RANKINGS FOR UMBILICAL CORD STEM CELL STORAGE COMPANIES
    151Table 46 FOCUS OF STEM AND PROGENITOR CELL THERAPY COMPANIES
    152Table 47 U.S. PATENT APPLICATIONS FROM JANUARY 1, 2001 THROUGH SEPTEMBER 8, 2005, WITH SELECTED STEM CELL SEARCH TERMS
    156Table 48 SELECTED U.S. STEM CELL PATENTS ISSUED BETWEEN JANUARY 2002 AND SEPTEMBER 2005
    157Table 49 DISAPPEARING NAMES IN REGENERATIVE MEDICINE
    161 LIST OF FIGURES

    Summary Figure:
    GLOBAL FORECAST OF REVENUES FOR STEM CELL AND CYTOKINE THERAPIES IN REGENERATIVE MEDICINE, 2003-2010 ($ BILLIONS)
    XXIIIFigure 1 HEMATOPOIESIS
    41Figure 2 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, 2003-2010 ($ MILLIONS)
    53Figure 3 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, 2003-2010 ($ MILLIONS)
    58Figure 4 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, 2003-2010 ($ MILLIONS)
    61Table 5 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS)
    68Figure 6 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, 2003-2010 ($ MILLIONS)
    74Figure 7 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS)
    82Figure 8 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, 2003-2010 ($ MILLIONS)
    87Figure 9 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, 2003-2010 ($ MILLION)
    120

    "There’s far too much unthinking respect given to authority,” Molly Ivins explained; “What you need is sustained outrage.”
    Kerr, Keirstead, McDonald, Stice and Jun Yan courageously work on ESCR to Cure SCI.

    Divisiveness comes from not following Christopher Reeve's ESCR lead.
    Young does ASCR.
    [I]I do not tear down CRPA, I ONLY make peopl

  7. #7
    Jawaid,

    I don't know enough about Tristem to comment definitively. I have not seen any evidence that they have any evidence to back up claims that their treatments will be beneficial for spinal cord injury.

    Wise.

    Quote Originally Posted by Jawaid
    Dear Leif Hope you will be fine. Never forget you are amongst my favourite CC Members. God bless you. Always smile and live happy.


    Dear Young TriStem is already treating patients here in pakistan and tell some good results too. When i did contact to them they are hopeful for my good recovery as you know i am incomplete with L1 compression. They say that i can regain bladder bowel and sexual function. Though not much confident but still reasonable for recovery.

    I need to know from you is that is TriStem reliable and i should go for treatment? Hope you will advise best. God bless you and keep you happy and healthy longer.

    Jawaid

  8. #8
    Senior Member
    Join Date
    May 2005
    Location
    Pakistan
    Posts
    1,169
    Dear Dr. Young

    Can you tell me something about the treatments of TriStem? Their procedure is called Retrodifferentation i think. What is this? Are they using Umbilical Cord Cells or any other type of cells? How much this way of treatment can be fruitful for Spinal injury?

    Jawaid

Similar Threads

  1. Stem cell study gets personal
    By Wise Young in forum Life
    Replies: 14
    Last Post: 11-19-2010, 06:17 AM
  2. Replies: 0
    Last Post: 01-18-2005, 03:52 AM
  3. Replies: 21
    Last Post: 12-02-2004, 04:01 PM
  4. World-wide stem cell research
    By Wise Young in forum Cure
    Replies: 4
    Last Post: 04-27-2003, 07:16 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •